Gennova Biopharmaceuticals, a 100 per cent vertically integrated arm of the Pune-based Emcure Pharmaceuticals has commercially rolled out PEGEX (Pegfilgrastim) in India. PEGEX (Pegfilgrastim) promises to reduce the duration of neutropenia and also the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for treatment of cancer. Gennova Biopharmaceuticals, CEO Dr Sanjay Singh said that PEGEX (Pegfilgrastim) will cost Rs 17,900. This is the most economical brand as compared to other pegfilgrastim brands, which are currently priced above Rs 27,000.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.